Trial Outcomes & Findings for Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension. (NCT NCT04702789)

NCT ID: NCT04702789

Last Updated: 2026-05-07

Results Overview

Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP is evaluated at 9:00 and at 11:00 hrs. (± 30 minutes). Both measurements and their average will be registered. Normal values are considered between 10 and 21 mmHg. Assessed at the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, reported only for first follow-up visit, second follow-up visit and final visit.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

28 participants

Primary outcome timeframe

Days: -30 (± 2) (eligibility visit), 0 (basal visit), 14 (± 2) (first follow-up visit), 30 (± 2) (second follow-up visit) and 60 (± 2) (final visit)

Results posted on

2026-05-07

Participant Flow

Participant randomization was conducted in a 1:1 ratio. When a participant enrolled both eyes in the study, both received the same treatment assignment.

Unit of analysis: eyes

Participant milestones

Participant milestones
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Overall Study
STARTED
12 23
14 24
Overall Study
COMPLETED
5 8
4 6
Overall Study
NOT COMPLETED
7 15
10 18

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Total
n=26 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=12 Participants
0 Participants
n=14 Participants
0 Participants
n=26 Participants
Age, Categorical
Between 18 and 65 years
4 Participants
n=12 Participants
5 Participants
n=14 Participants
9 Participants
n=26 Participants
Age, Categorical
>=65 years
8 Participants
n=12 Participants
9 Participants
n=14 Participants
17 Participants
n=26 Participants
Age, Continuous
63.0 years
STANDARD_DEVIATION 12.2 • n=12 Participants
70.9 years
STANDARD_DEVIATION 7.9 • n=14 Participants
67.3 years
STANDARD_DEVIATION 10.73 • n=26 Participants
Sex: Female, Male
Female
8 Participants
n=12 Participants
9 Participants
n=14 Participants
17 Participants
n=26 Participants
Sex: Female, Male
Male
4 Participants
n=12 Participants
5 Participants
n=14 Participants
9 Participants
n=26 Participants
Race and Ethnicity Not Collected
0 Participants
Race and Ethnicity were not collected from any participant.
Region of Enrollment
Mexico
12 participants
n=12 Participants
14 participants
n=14 Participants
26 participants
n=26 Participants
Best Corrected Visual Acuity (BCVA)
0.71 decimals
STANDARD_DEVIATION 0.26 • n=12 Participants
0.71 decimals
STANDARD_DEVIATION 0.21 • n=14 Participants
0.71 decimals
STANDARD_DEVIATION 0.23 • n=26 Participants

PRIMARY outcome

Timeframe: Days: -30 (± 2) (eligibility visit), 0 (basal visit), 14 (± 2) (first follow-up visit), 30 (± 2) (second follow-up visit) and 60 (± 2) (final visit)

Population: The evaluated population for this outcome measure was the PP population (subjects who finished the study without presenting any mayor deviations to protocol)

Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP is evaluated at 9:00 and at 11:00 hrs. (± 30 minutes). Both measurements and their average will be registered. Normal values are considered between 10 and 21 mmHg. Assessed at the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, reported only for first follow-up visit, second follow-up visit and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=8 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=6 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Change in Intraocular Pressure (IOP)
V2 Change in IOP 9AM
-5.94 mmHg
Standard Deviation 2.21
-7.0 mmHg
Standard Deviation 3.54
Change in Intraocular Pressure (IOP)
FV Change in IOP 11AM
-5.75 mmHg
Standard Deviation 2.66
-5.50 mmHg
Standard Deviation 1.38
Change in Intraocular Pressure (IOP)
V1 Change in IOP 9AM
-4.25 mmHg
Standard Deviation 1.49
-5.17 mmHg
Standard Deviation 2.48
Change in Intraocular Pressure (IOP)
V1 Change in IOP 11AM
-3.31 mmHg
Standard Deviation 2.09
4.33 mmHg
Standard Deviation 3.39
Change in Intraocular Pressure (IOP)
V2 Change in IOP 11AM
-5.69 mmHg
Standard Deviation 1.98
-6.80 mmHg
Standard Deviation 2.39
Change in Intraocular Pressure (IOP)
FV Change in IOP 9AM
-5.94 mmHg
Standard Deviation 2.34
-5.0 mmHg
Standard Deviation 1.79

SECONDARY outcome

Timeframe: Days: -30 (± 2) (eligibility visit), 0 (basal visit [BV]), 14 (± 2) (first follow-up visit [V1]), 30 (± 2) (second follow-up visit [V2]) and 60 (± 2) (final visit [FV])

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Visual acuity (VA) is a test of visual function. It will be evaluated with the Snellen chart. The Snellen chart is the standard tool used to evaluate visual acuity. It was located in a place with adequate lighting, natural or artificial and at a distance of 3 meters from the subject to be evaluated. The contralateral eye to which it will be evaluated is covered, then the examiner detects until the line can clearly see the letters given he or she a score, the normal score for a VA is 20/20.This score can be expressed in fraction (i.e. 20/20) decimal (i.e. 1.0), or LogMAR (i.e. 0) formats. In this study, VA is expressed in decimal format. In decimal format, a lower number is a worse outcome. BCVA was compared between groups and between visits. Assessed at the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, reported only for first follow-up visit, second follow-up visit and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Best Corrected Visual Acuity (BCVA)
V1 BVCA
0.69 decimal
Standard Deviation 0.25
0.72 decimal
Standard Deviation 0.23
Best Corrected Visual Acuity (BCVA)
V2 BVCA
0.70 decimal
Standard Deviation 0.27
0.74 decimal
Standard Deviation 0.20
Best Corrected Visual Acuity (BCVA)
VF BVCA
0.79 decimal
Standard Deviation 0.23
0.68 decimal
Standard Deviation 0.30

SECONDARY outcome

Timeframe: Days: 0 (basal visit) and 60 (± 2) (final visit)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Both clinical and imaging evaluation will be performed. For clinical evaluation, after the application of a topical ophthalmic mydriatic (tropicamide 0.8% / phenylephrine 5%), indirect ophthalmoscopy will be performed through the aid of a fundus lens in a slit lamp. For imaging, optic coherence tomography (OCT) will be used. Assessed and reported only for the basal visit and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Optic Nerve Cup/Disc Ratio (Baseline Vist vs Final Visit)
BV Cup/disk ratio
0.69 ratio
Standard Deviation 0.16
0.68 ratio
Standard Deviation 0.22
Optic Nerve Cup/Disc Ratio (Baseline Vist vs Final Visit)
FV Cup/disk ratio
0.62 ratio
Standard Deviation 0.17
0.72 ratio
Standard Deviation 0.12

SECONDARY outcome

Timeframe: Days: 0 (basal visit) and 60 (± 2) (final visit)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Spectral domain OCT is a non invasive tool that will be used to evaluate quantitatively the thickness of retinal nerve fibers and ganglion cell layers. The mean observed in the nerve fibers and ganglion cell thickness was calculated. This was assessed and reported only for the basal and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Mean Value in Nerve Fibers and Ganglion Cell Thickness
BV Nerve fibers
80.1 micrometers
Standard Deviation 16.0
74.4 micrometers
Standard Deviation 13.3
Mean Value in Nerve Fibers and Ganglion Cell Thickness
BV Ganglion cell thickness
75.8 micrometers
Standard Deviation 15.1
69.1 micrometers
Standard Deviation 7.20
Mean Value in Nerve Fibers and Ganglion Cell Thickness
FV Nerve fibers
82.6 micrometers
Standard Deviation 11.0
72.6 micrometers
Standard Deviation 10.8
Mean Value in Nerve Fibers and Ganglion Cell Thickness
FV Ganglion cell thickness
79.9 micrometers
Standard Deviation 14.7
71.7 micrometers
Standard Deviation 9.15

SECONDARY outcome

Timeframe: Days: -30 (± 2) (eligibility visit), 0 (basal visit) and 60 (± 2) (final visit)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Through a fundus camera a photograph will be taken to obtain a faithful record of any possible changes to the optic nerve head characteristics. Its classification as "small", "medium" or "large" relied on the expertise of the PI, the percentage of cases in each classification ("small", "medium" or "large") was reported. Assessed and reported only for the basal visit and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Optic Nerve Image
BV "Large" Optic Nerve
4 participants
4 participants
Optic Nerve Image
FV "Small" Optic Nerve
0 participants
0 participants
Optic Nerve Image
FV "Medium" Optic Nerve
12 participants
14 participants
Optic Nerve Image
FV "Large" Optic Nerve
0 participants
0 participants
Optic Nerve Image
BV "Small" Optic Nerve
0 participants
2 participants
Optic Nerve Image
BV "Medium" Optic Nerve
8 participants
8 participants

SECONDARY outcome

Timeframe: Days: 0 (basal visit) and 60 (± 2) (final visit)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Measured through ultrasonic pachymetry, three assessments will be performed, these and its average will be recorded. Assessed and reported for the basal visit and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Central Corneal Thickness (CCT)
BV CCT
536 micrometers
Standard Deviation 42.7
518 micrometers
Standard Deviation 32.9
Central Corneal Thickness (CCT)
FV CCT
540 micrometers
Standard Deviation 57.5
528 micrometers
Standard Deviation 27.4

SECONDARY outcome

Timeframe: Days: 0 (basal visit) and 60 (± 2) (final visit)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Visual fields will be assessed using standard automated SITA (Swedish Interactive Thresholding Algorithm) white-on-white perimetry performed with a Humphrey perimeter. To be considered reliable, fixation losses, false positives, and false negatives must be less than 20%. The mean deviation (MD) was recorded, which is a measure of overall field loss. The standard deviation of the pattern was also recorded, which is a measure of focal loss or variability within the field. A higher score is a worse result. The theoretical value or reported range for the average deviation is from +2.00 to -35 dB.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Change in Visual Fields
BV Change in visual field
-4.25 score on a scale
Standard Deviation 6.69
-7.50 score on a scale
Standard Deviation 8.33
Change in Visual Fields
FV Change in visual field
-0.80 score on a scale
Standard Deviation 5.47
-3.08 score on a scale
Standard Deviation 4.05

SECONDARY outcome

Timeframe: Days: 0 (basal visit, BV), 14 (± 2) (first follow-up visit, V1), 30 (± 2) (second follow-up visit, V2) and 60 (± 2) (final visit, FV)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

By means of a slit lamp chemosis will be evaluated. Chemosis will be evaluated as present (if conjunctiva separates from the sclera in ≥ 1/3 of the palpebral opening area or if it exceeds the eyelid's gray line) or absent. The number and percentage of participants in each category was reported.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Change in Ocular Surface Integrity (Chemosis)
V2 Chemosis · Absent
12 Participants
14 Participants
Change in Ocular Surface Integrity (Chemosis)
FV Chemosis · Present
0 Participants
0 Participants
Change in Ocular Surface Integrity (Chemosis)
FV Chemosis · Absent
12 Participants
14 Participants
Change in Ocular Surface Integrity (Chemosis)
BV Chemosis (Absent or not absent) · Present
0 Participants
0 Participants
Change in Ocular Surface Integrity (Chemosis)
BV Chemosis (Absent or not absent) · Absent
12 Participants
14 Participants
Change in Ocular Surface Integrity (Chemosis)
V1 Chemosis · Present
0 Participants
0 Participants
Change in Ocular Surface Integrity (Chemosis)
V1 Chemosis · Absent
12 Participants
14 Participants
Change in Ocular Surface Integrity (Chemosis)
V2 Chemosis · Present
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Day: 75 (± 3) (safety call)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Presence/absence adverse events, defined as the appearance of any unfavorable reaction in a patient participating in a clinical investigation in which any pharmaceutical product is being administered, regardless of the causal attribution.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Number of Adverse Events
32 adverse events
43 adverse events

SECONDARY outcome

Timeframe: Days: -30 (± 2) (eligibility visit), 0 (basal visit), 14 (± 2) (first follow-up visit), 30 (± 2) (second follow-up visit) and 60 (± 2) (final visit)

Population: This outcome measure considered the Intention-To-Treat (ITT) population, all participants who were randomized and exposed to treatment, regardless of whether they finished the study.

Ocular Comfort Index (OCI) Questionnaire will be used for evaluation of tolerability through incidence and severity of dry eye symptoms in a scale from 0 to 100. Greater scores mean a worse outcome.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 Participants
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Changes in Ocular Comfort Index
Eligibility visit
30.5 score on a scale
Standard Deviation 15.7
30.1 score on a scale
Standard Deviation 5.7
Changes in Ocular Comfort Index
first follow-up visit
39.2 score on a scale
Standard Deviation 12.8
29.4 score on a scale
Standard Deviation 5.90
Changes in Ocular Comfort Index
second follow-up visit
33.0 score on a scale
Standard Deviation 10.9
29.1 score on a scale
Standard Deviation 7.97
Changes in Ocular Comfort Index
Basal visit
33.2 score on a scale
Standard Deviation 8.84
27.2 score on a scale
Standard Deviation 8.68
Changes in Ocular Comfort Index
final visit
29.8 score on a scale
Standard Deviation 17.6
23.6 score on a scale
Standard Deviation 15.6

SECONDARY outcome

Timeframe: Days: 0 (basal visit, BV), 14 (± 2) (first follow-up visit, V1), 30 (± 2) (second follow-up visit, V2) and 60 (± 2) (final visit, FV)

Population: This result was calculated using the intention-to-treat (ITT) population, that is, all participants who were randomly assigned and received treatment, regardless of whether they completed the study. When using the ITT population, the number of cases varies across visits, as some participants dropped out of the study during its course.

By means of a slit lamp conjunctival hyperemia will be evaluated. Conjunctival hyperemia will be graded according to Efron's scale (5 grades: Normal (0), Very Mild (I), Mild (II), Moderate (3), and Severe (4)).

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=23 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=24 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V1 Conjunctival Hyperemia : Moderate (III)
1 cases (eyes)
2 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V1 Conjunctival Hyperemia : Severe (III)
0 cases (eyes)
0 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V2 Conjunctival Hyperemia : Normal (0)
4 cases (eyes)
2 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V2 Conjunctival Hyperemia : Very mild (I)
8 cases (eyes)
7 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V2 Conjunctival Hyperemia : Mild (II)
5 cases (eyes)
4 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V2 Conjunctival Hyperemia : Moderate (III)
0 cases (eyes)
3 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V2 Conjunctival Hyperemia : Severe (III)
0 cases (eyes)
0 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
FV Conjunctival Hyperemia : Normal (0)
4 cases (eyes)
2 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
FV Conjunctival Hyperemia : Very mild (I)
6 cases (eyes)
2 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
FV Conjunctival Hyperemia : Mild (II)
1 cases (eyes)
2 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
FV Conjunctival Hyperemia : Moderate (III)
0 cases (eyes)
3 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
FV Conjunctival Hyperemia : Severe (III)
0 cases (eyes)
0 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V1 Conjunctival Hyperemia : Normal (0)
4 cases (eyes)
0 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V1 Conjunctival Hyperemia : Very mild (I)
11 cases (eyes)
13 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
V1 Conjunctival Hyperemia : Mild (II)
3 cases (eyes)
8 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
BV Conjunctival Hyperemia : Mild (II)
4 cases (eyes)
6 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
BV Conjunctival Hyperemia : Moderate (III)
1 cases (eyes)
2 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
BV Conjunctival Hyperemia : Severe (III)
0 cases (eyes)
0 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
BV Conjunctival Hyperemia : Normal (0)
6 cases (eyes)
4 cases (eyes)
Change in Ocular Surface Integrity (Conjunctival Hyperemia)
BV Conjunctival Hyperemia : Very mild (I)
12 cases (eyes)
12 cases (eyes)

OTHER_PRE_SPECIFIED outcome

Timeframe: Days: -30 (± 2) (eligibility visit), 0 (basal visit), 14 (± 2) (first follow-up visit), 30 (± 2) (second follow-up visit) and 60 (± 2) (final visit)

Population: The evaluated population for this outcome measure was the PP population (subjects who finished the study without presenting any mayor deviations to protocol). Study participants were permitted to include both eyes; accordingly, the number of cases was documented to provide a more precise description of the results from patients with bilateral inclusion.

Percentage of cases who reached a reduction in IOP within the following ranges: ≤12, ≤13, ≤14, ≤15, or ≤18 mmHg. Each range is a classification and the percentage is calculated with the counts of cases in each classification. PIO was assessed in the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, and was reported for the first follow-up visit, second follow-up visit, and final visit. The initial objective of the study was to report the percentage of patients who achieved a specific reduction in intraocular pressure (IOP). However, because the study ended early, the number of participants was limited, and both eyes per patient were included, we chose to present the full dataset in order to provide a more comprehensive report.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=8 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=6 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 11AM · ≤ 13 mmHg
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 9AM · ≤ 13 mmHg
2 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 9AM · ≤ 14 mmHg
0 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 11AM · ≤ 18 mmHg
1 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 11AM · ≥ 19 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 9AM · ≤ 15 mmHg
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 9AM · ≤ 18 mmHg
3 Cases (eyes)
3 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 9AM · ≥ 19 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 11AM · ≤ 12 mmHg
5 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 11AM · ≤ 13 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 11AM · ≤ 14 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 11AM · ≤ 15 mmHg
2 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 9AM · ≤ 15 mmHg
1 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 9AM · ≤ 15 mmHg
1 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 9AM · ≤ 12 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 9AM · ≤ 13 mmHg
0 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 9AM · ≤ 14 mmHg
4 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 9AM · ≤ 18 mmHg
2 Cases (eyes)
3 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 9AM · ≥ 19 mmHg
1 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 11AM · ≤ 12 mmHg
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 11AM · ≤ 14 mmHg
4 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 11AM · ≤ 15 mmHg
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 11AM · ≤ 18 mmHg
3 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V1 11AM · ≥ 19 mmHg
1 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 9AM · ≤ 12 mmHg
2 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 9AM · ≤ 13 mmHg
3 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 9AM · ≤ 14 mmHg
1 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 9AM · ≤ 18 mmHg
1 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 9AM · ≥ 19 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 11AM · ≤ 12 mmHg
2 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 11AM · ≤ 13 mmHg
3 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 11AM · ≤ 14 mmHg
2 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 11AM · ≤ 15 mmHg
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 11AM · ≤ 18 mmHg
1 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
V2 11AM · ≥ 19 mmHg
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in mmHg
VF 9AM · ≤ 12 mmHg
3 Cases (eyes)
0 Cases (eyes)

OTHER_PRE_SPECIFIED outcome

Timeframe: Days: -30 (± 2) (eligibility visit), 0 (basal visit), 14 (± 2) (first follow-up visit), 30 (± 2) (second follow-up visit) and 60 (± 2) (final visit)

Population: The evaluated population for this outcome measure was the PP population (subjects who finished the study without presenting any mayor deviations to protocol). Study participants were permitted to include both eyes; accordingly, the number of cases was documented to provide a more precise description of the results from patients with bilateral inclusion

Cases who demonstrated decrease in IOP within the following percentage ranges: ≥ 20%, ≥ 25%, ≥ 30%, y ≥ 35%. Each range is a classification and the percentage is calculated with the counts of cases in each classification. PIO was assessed in the eligibility visit, basal visit, first follow-up visit, second follow-up visit, and final visit, and was reported for the first follow-up visit, second follow-up visit, and final visit.

Outcome measures

Outcome measures
Measure
Arm 1; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=8 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Arm 2; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=6 Cases (eyes)
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 9AM · ≥ 30%
2 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 11AM · < 20%
1 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 11AM · ≥ 20%
0 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 9AM · < 20%
4 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 9AM · ≥ 20%
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 9AM · ≥ 25%
2 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 9AM · ≥ 35%
0 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 11AM · < 20%
4 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 11AM · ≥ 20%
2 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 11AM · ≥ 25%
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 11AM · ≥ 30%
2 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V1 11AM · ≥ 35%
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 9AM · < 20%
1 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 9AM · ≥ 20%
1 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 9AM · ≥ 25%
0 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 9AM · ≥ 30%
3 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 9AM · ≥ 35%
3 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 11AM · ≥ 25%
2 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 11AM · ≥ 30%
2 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
V2 11AM · ≥ 35%
3 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 9AM · < 20%
2 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 9AM · ≥ 20%
1 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 9AM · ≥ 25%
0 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 9AM · ≥ 30%
1 Cases (eyes)
2 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 9AM · ≥ 35%
4 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 11AM · < 20%
2 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 11AM · ≥ 20%
1 Cases (eyes)
1 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 11AM · ≥ 25%
0 Cases (eyes)
4 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 11AM · ≥ 30%
1 Cases (eyes)
0 Cases (eyes)
Percentage of Cases Who Reached a Specific IOP Decrease in Percentage
VF 11AM · ≥ 35%
4 Cases (eyes)
1 Cases (eyes)

Adverse Events

Ocular; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®

Serious events: 0 serious events
Other events: 14 other events
Deaths: 0 deaths

Ocular; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®

Serious events: 0 serious events
Other events: 18 other events
Deaths: 0 deaths

Systemic: Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®

Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths

Systemic: Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®

Serious events: 0 serious events
Other events: 4 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Ocular; Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=23 participants at risk
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Ocular; Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=24 participants at risk
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Systemic: Dorzolamide-timolol-brimonidine and Latanoprost; Krytantek Ofteno PF® and Gaap Ofteno PF®
n=12 participants at risk
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Krytantek Ofteno® (dorzolamide 2%, timolol 0.5% and brimonidine 0.2%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol-brimonidine and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Krytantek Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Systemic: Dorzolamide-timolol and Latanoprost; Eliptic Ofteno PF® and Gaap Ofteno PF®
n=14 participants at risk
Application of Gaap Ofteno® (latanoprost 0.005%; preservative free) ophthalmic solution every 24 hours at 21:30 hours (± 15 min) for the duration of the study (total exposure: 90 days). One month after initiating Gaap Ofteno® instillation, application of Eliptic Ofteno® (dorzolamide 2% and timolol 0.5%; preservative free) ophthalmic solution will be added every 12 hours at 9:00 and 21:00 hours (± 10 min) (total exposure: 60 days). Dorzolamide-timolol and latanoprost: Application of Gaap Ofteno PF® every 24 hrs for 30 days plus concomitant application of Eliptic Ofteno PF® every 12 hours for 60 days. Total intervention time: 90 days.
Eye disorders
Conjunctivitis
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
4.2%
1/24 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Ocular paint
8.7%
2/23 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
2/24 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Photophobia
4.3%
1/23 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
4.2%
1/24 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Conjunctival hyperemia
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
2/24 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Ocular hyperemia
8.7%
2/23 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
16.7%
4/24 • Number of events 4 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Eye irritation
17.4%
4/23 • Number of events 4 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
29.2%
7/24 • Number of events 7 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Increased tearing
8.7%
2/23 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
4.2%
1/24 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
dry eye
13.0%
3/23 • Number of events 3 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
2/24 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Blepharitis
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
2/24 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Itchy eye
17.4%
4/23 • Number of events 4 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
37.5%
9/24 • Number of events 9 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Itching of the eyelid
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
12.5%
3/24 • Number of events 3 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Eye discharge
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
20.8%
5/24 • Number of events 5 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Foreign body in the eyes
8.7%
2/23 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
29.2%
7/24 • Number of events 7 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Eye disorders
Blurred vision
8.7%
2/23 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
16.7%
4/24 • Number of events 4 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Nervous system disorders
Headache
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
33.3%
4/12 • Number of events 4 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
14.3%
2/14 • Number of events 2 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Respiratory, thoracic and mediastinal disorders
Nasopharyngitis
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
1/12 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Nervous system disorders
Dizziness
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
7.1%
1/14 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Nervous system disorders
Hypoesthesia
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/12 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
7.1%
1/14 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Gastrointestinal disorders
Gastrointestinal infection
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
1/12 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Nervous system disorders
Neuralgia
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
1/12 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
Ear and labyrinth disorders
Vertigo
0.00%
0/23 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/24 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
8.3%
1/12 • Number of events 1 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.
0.00%
0/14 • From day 0 (basal visit) to the safety call on day 75 (±3 days)
Ocular adverse events are recorded for each case (eye) included in the study. In contrast, systemic adverse events are recorded per participant.

Additional Information

Alejandra Sanchez-Ríos M.D.

Laboratorios Sophia

Phone: :+52 (33) 3001 4200

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place